Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Gets Price Target Cut from Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its target price trimmed by Royal Bank Of Canada to $1.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a sector perform rating on the stock.

Several other analysts have also weighed in on the company. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Chardan Capital downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price for the company. in a research note on Tuesday, August 18th. Jefferies Financial Group downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a research note on Monday. TD Cowen cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their target price for the stock from $20.00 to $4.00 in a report on Wednesday, September 2nd. Finally, Weiss Ratings raised shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Eyepoint Pharmaceuticals presently has an average rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT stock opened at $0.43 on Tuesday. Eyepoint Pharmaceuticals has a fifty-two week low of $0.39 and a fifty-two week high of $19.11. The stock’s fifty day moving average price is $3.99 and its two-hundred day moving average price is $10.03. The company has a market cap of $36.91 million, a PE ratio of -0.11 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. On average, equities analysts predict that Eyepoint Pharmaceuticals will post -3.50 EPS for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Commodore Capital LP bought a new stake in Eyepoint Pharmaceuticals in the first quarter valued at approximately $36,414,000. Hsbc Holdings PLC acquired a new stake in Eyepoint Pharmaceuticals during the 1st quarter valued at approximately $10,743,000. Janus Henderson Group PLC raised its holdings in Eyepoint Pharmaceuticals by 22.6% during the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares during the last quarter. Stempoint Capital LP raised its holdings in Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in Eyepoint Pharmaceuticals during the 1st quarter worth approximately $3,869,000. 99.41% of the stock is owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its Q3 2027 EPS forecast to $0.45 from a projected loss of $0.45, suggesting the analyst still sees a potential path to profitability in the longer term. However, the firm maintained a Neutral rating. HC Wainwright estimates
• Neutral Sentiment: Several firms maintained cautious views: HC Wainwright reaffirmed Neutral, Mizuho assigned Neutral, and Laidlaw reaffirmed Hold. These ratings indicate limited conviction in a near-term recovery following the clinical setback. HC Wainwright rating Mizuho rating Laidlaw rating
• Neutral Sentiment: Large call-option activity suggests some traders are positioning for a rebound, but options activity is speculative and does not change the company’s fundamental outlook. EyePoint call options
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS estimate to a loss of $0.85 from $0.60 and cut its FY2026 estimate to a loss of $3.40 from $3.15, reflecting worsening near-term expectations. Revised EPS estimates
• Negative Sentiment: JPMorgan issued an Underweight rating, while Jefferies and Guggenheim downgraded the stock, adding further institutional pressure after the failed LUCIA trial. JPMorgan rating Jefferies downgrade Guggenheim downgrade
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities claims related to the LUCIA trial disclosure and the resulting shareholder losses. The investigation adds legal and reputational risk, although it does not establish wrongdoing. Levi & Korsinsky investigation

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.